Stem Cell Transplantation

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

Rituximab With High-dose Sequential Chemo Fails to Improve DLBCL Outcomes

By

Frontline treatment with rituximab plus high-dose sequential chemotherapy with autologous HSCT failed to improve progression-free or overall survival compared with R-CHOP in patients with diffuse large B-cell lymphoma.

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

Immune Cells Are Biologically Older After Hematopoietic Cell Transplantation

By

Hematopoietic stem cell transplantation (HCT) is found to increase expression of a genetic code used to make proteins, leading to a biological aging of immune cells equivalent to 30 years of chronological age.

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

Ipilumumab Feasible for Recurrent Hematologic Cancers After Allogeneic Stem Cell Transplant

By

Repeat doses of ipilimumab can restore a complete remission in patients with advanced blood cancers who relapse after allogeneic hematopoietic stem cell transplant (alloHSCT).

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

Autologous Stem Cell Transplant Safe as Standard of Care in Patients With HIV-Associated Lymphoma

By

Recent results from a multicenter, phase 2 trial suggest that patients with HIV and aggressive lymphoma should receive autologous stem cell transplant as standard of care. Risk of serious complications after transplant in these patients is equal to that of patients without HIV.

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

Novel Antibody-Drug Conjugate Bridges Patients With Relapsed ALL to Stem Cell Transplant

By

In a randomized phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with ALL whose disease had relapsed following standard therapies, qualified for stem cell transplants after treatment with the drug.

Meta-analysis Confirms Lenalidomide Maintenance Prolongs Overall Survival in Multiple Myeloma

Meta-analysis Confirms Lenalidomide Maintenance Prolongs Overall Survival in Multiple Myeloma

By

Lenalidomide maintenance after high-dose melphalan and autologous stem cell transplant (ASCT) significantly prolonged overall survival in patients with multiple myeloma compared with no maintenance, a meta-analysis of 3 randomized controlled trials presented at the 2016 ASCO Annual Meeting has found.

Upfront ASCT Preferred Treatment for Younger Patients With Newly Diagnosed Multiple Myeloma

Upfront ASCT Preferred Treatment for Younger Patients With Newly Diagnosed Multiple Myeloma

By

Upfront autologous stem cell transplantation (ASCT) remains the preferred treatment for patients age 65 years or younger with newly diagnosed multiple myeloma, according to phase 3 study results reported at the 2016 ASCO Annual Meeting.

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

Corticosteroid Prophylaxis Reduces Risk of Graft-versus-host Disease in Patients Undergoing Haploidentical Transplantation

By

Prophylactic low-dose corticosteroid was significantly associated with relatively low risk of GVHD grades II to IV and rapid platelet recovery in patients undergoing haploidentical transplantation.

Study Assesses Risk Factors for Depression Among HSCT Survivors

Study Assesses Risk Factors for Depression Among HSCT Survivors

By

Current presence of pain was associated with both greater depression and fatigue in survivors of hematopoietic stem cell transplantation (HSCT).

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Antibody Therapy Beneficial for Patients With Leukemia Undergoing Stem Cell Transplant

Results for patients with acute leukemia that received the antibody showed lower incidence of chronic graft-versus-host disease post-transplant.

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

Allogeneic SCT: A Curative Strategy for Primary Refractory AML

By

For patients with refractory acute myeloid leukemia (AML), employment of allogeneic stem cell transplantation may be a valid treatment strategy.

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

Ponatinib Ups Overall Survival in Patients with CP-CML and T315I Mutation

By

For patients with chronic phase chronic myeloid leukemia (CP-CML) and the T315I mutation, ponatinib treatment may offer longer overall survival.

Biologic Age Need Not be a Limiting Factor for Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML)

By

More than 40% of older patients with AML can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study.

Sleep Deprivation Affects Stem Cells and Reduces Transplant Efficiency

By

A sleep deficit of just 4 hours affects the ability of blood and immune-system stem cells to migrate to the proper spots in the bone marrow of recipient mice and churn out the cell types necessary to reconstitute a damaged immune system by as much as 50%.

High-Dose Chemo and Stem Cell Transplantation Results in Long-Term Survival for Patients With Amyloidosis

By

Patients with light-chain amyloidosis who are treated with high-dose chemotherapy and autologous stem cell transplantation have the greatest success for long-term survival.

Researchers discover a potential biomarker for AML relapse after stem cell transplant

By

Targeting exhausted immune cells may change the prognosis for patients with AML relapse after a stem cell transplant, according to a recent study.

Stem cell transplantation improves outcomes for children with rare form of leukemia

Stem cell transplantation improves outcomes for children with rare form of leukemia

By

Greatly improved outcomes have been observed in using stem cell transplantation to treat patients with juvenile myelomonocytic leukemia (JMML), a rare form of blood cancer.

Experimental treatment sends deadly leukemia into remission

By

An experimental new treatment approach could buy patients with a rare and dangerous leukemia type the time to obtain a stem cell transplant.

Younger, unrelated donors with high T cell counts make better matches for patients undergoing stem cell transplant

By

Measuring the T lymphocyte count in stem cell transplant donors can improve matchmaking for patients in need of an allogeneic stem cell transplant.

Patients at risk for stem cell transplant complications identified

By

Lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival, according to findings from a phase 2 clinical trial.

Clinical trial reduces the stress of stem cell transplant patients' caregivers

By

The stress of caregivers of patients receiving stem cell transplantation can be successfully reduced by an intervention, according to a randomized controlled trial.

Test predicts response to treatment for graft-versus-host disease (GVHD)

By

A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.

Immunotherapy shows clinical benefit in relapsed transplant recipients

Immunotherapy shows clinical benefit in relapsed transplant recipients

By

Almost half of patients with blood cancer who had relapsed following allogeneic stem cell transplantation benefitted from treatment with the immune checkpoint blocker ipilimumab.

Study shows need for psychosocial support for patients undergoing hematopoietic stem cell transplant

Study shows need for psychosocial support for patients undergoing hematopoietic stem cell transplant

According to a recent study, patients undergoing hematopoietic stem cell transplantation (HCT) reported a steep problems and substantially worsening depression during hospitalization.

Parents resilient after their children undergo stem cell transplant

By

A recent study shows that, in the case of stem cell transplantation in a child, parents feel increased distress at the time of the procedure, but eventually recover.

Advances in cell engineering improve prognosis of haploidentical stem cell transplantation

By

Genetically engineered cell therapies may bring hope to patients for whom standard treatments have been unsuccessful, according to two separate studies presented at the 2013 ASH Annual Meeting, in New Orleans, Louisiana.

Age alone should not limit access to stem cell transplants for patients with MDS

By

Patients with myelodysplastic syndrome age 66 to 74 years did as well with stem cell transplantation as patients age 60 to 65 years. This research was presented at the 2013 ASH Annual Meeting, in New Orleans.

Bortezomib regimen improves stem cell transplantation outcomes

By

Adding bortezomib to standard preventive therapy for GVHD results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to research presented at the 2013 ASH Annual Meeting, in New Orleans.

Umbilical cord blood stem cells treat leukemia and lymphoma

Umbilical cord blood stem cells treat leukemia and lymphoma

By

Growing cord blood stem cells in a laboratory before transplanting them into patients with leukemia, lymphoma, and other blood cancers significantly improves survival, according to a new study.

Supporting others brings healing to breast cancer survivors

By

A new study finds that survivors of hematopoietic stem cell transplant, an aggressive treatment for blood cancers, benefited from a two-part peer support process. The authors called this peer support process "expressive helping."

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs